JP2000507974A - 多糖―ペプチド複合体 - Google Patents
多糖―ペプチド複合体Info
- Publication number
- JP2000507974A JP2000507974A JP10533768A JP53376898A JP2000507974A JP 2000507974 A JP2000507974 A JP 2000507974A JP 10533768 A JP10533768 A JP 10533768A JP 53376898 A JP53376898 A JP 53376898A JP 2000507974 A JP2000507974 A JP 2000507974A
- Authority
- JP
- Japan
- Prior art keywords
- polysaccharide
- peptide
- group
- repeating units
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(i)少なくとも6つのアミノ酸残基からなり、そのうちの少なくとも1 つがシステイン残基であるペプチド部分、 (ii)少なくとも4つの繰り返し単位からなる多糖鎖、および (iii)該システイン残基のチオール基と結合し、かつ(a)該多糖鎖の天然 のアミノ、ヒドロキシまたはカルボキシル基、または(b)該多糖鎖の天然のN −アシル基の加水分解で生じたアミノ基、または(c)該多糖鎖の天然のアミノ 、ヒドロキシまたはカルボキシル基に結合するスペーサー部分から由来する該多 糖鎖に誘導された官能性基と結合したリンカー部分からなることを特徴とする、 多糖が免疫原性である多糖−ペプチド複合体。 2.ペプチドが、システイン残基を含め、6〜200アミノ酸残基を含有する 請求項1記載の複合体。 3.ペプチドが、システイン残基を含め、10〜150アミノ酸残基を含有す る請求項2記載の複合体。 4.ペプチドが、システイン残基を含め、15〜100アミノ酸残基を含有す る請求項3記載の複合体。 5.ペプチドが、システイン残基を含め、20〜50アミノ酸残基を含有する 請求項4記載の複合体。 6.システイン残基が、ペプチド部分のN−またはC−末端に位置する請求項 1〜5いずれか1つに記載の複合体。 7.ペプチドが、T−依存性エピトープを含有する請求項1〜6いずれか1つ に記載の複合体。 8.多糖が、細菌性リポ多糖類のO−特異性鎖、無毒化細菌性リポ多糖類およ び莢膜多糖類から選択される天然多糖である請求項1〜7いずれか1つに記載の 複合体。 9.多糖が、制御された酸性または塩基性加水分解によるN−アセチル基を含 む 天然多糖から由来する請求項1〜7いずれか1つに記載の複合体。 10.多糖が莢膜多糖から選択される天然物である請求項9記載の複合体。 11.多糖が4〜3000繰り返し単位からなる請求項1〜10記載の複合体 。 12.多糖が4〜1000繰り返し単位からなる請求項11記載の複合体。 13.多糖が7〜700繰り返し単位からなる請求項12記載の複合体。 14.ペプチド1モルにつき、50モルの繰り返し単位(1:50)から、ペ プチド1モルにつき、1モルの繰り返し単位(1:1)までを含有する請求項1 〜13いずれか1つに記載の複合体。 15.ペプチド1モルにつき、30モルの繰り返し単位(1:30)から、ペ プチド1モルにつき、3モルの繰り返し単位(1:3)までを含有する請求項1 4に記載の複合体。 16.ペプチド1モルにつき、20モルの繰り返し単位(1:20)から、ペ プチド1モルにつき、5モルの繰り返し単位(1:5)までを含有する請求項1 5に記載の複合体。 17.請求項1〜16いずれか1つに記載の複合体と、医薬上許容される希釈 剤または担体からなる医薬組成物。 18.アジュバントを含まない請求項17記載の組成物。 19.少なくとも6つのアミノ酸残基を有し、そのうちの少なくとも1つがシ ステイン残基であるペプチドを、該システイン残基のチオール基を介してリンカ ーとカップリングさせ、また、少なくとも4つの繰り返し単位からなる多糖鎖、 とりわけ、免疫原性多糖鎖を、(a)該多糖鎖の天然のアミノ、ヒドロキシまた はカルボキシル基、または(b)該多糖鎖の天然のN−アシル基の加水分解で生 じたアミノ基、または(c)該多糖鎖の天然のアミノ、ヒドロキシまたはカルボ キシル基に結合するスペーサー部分から由来する該多糖鎖に誘導された官能性基 を介して該リンカーとカップリングさせることを特徴とする該ペプチドを該多糖 と結合させる方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97100884.2 | 1997-01-21 | ||
EP97100884 | 1997-01-21 | ||
PCT/EP1998/000654 WO1998031393A2 (en) | 1997-01-21 | 1998-01-21 | Polysaccharide-peptide-conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000507974A true JP2000507974A (ja) | 2000-06-27 |
JP4290766B2 JP4290766B2 (ja) | 2009-07-08 |
Family
ID=8226387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53376898A Expired - Fee Related JP4290766B2 (ja) | 1997-01-21 | 1998-01-21 | 多糖―ペプチド複合体 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6472506B1 (ja) |
EP (1) | EP0959905B1 (ja) |
JP (1) | JP4290766B2 (ja) |
KR (1) | KR100593466B1 (ja) |
AT (1) | ATE451124T1 (ja) |
AU (1) | AU722315B2 (ja) |
CA (1) | CA2246760C (ja) |
DE (1) | DE69841362D1 (ja) |
DK (1) | DK0959905T3 (ja) |
ES (1) | ES2335557T3 (ja) |
NO (1) | NO323870B1 (ja) |
NZ (1) | NZ331578A (ja) |
PT (1) | PT959905E (ja) |
WO (1) | WO1998031393A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006511465A (ja) * | 2002-08-30 | 2006-04-06 | カイロン ソチエタ ア レスポンサビリタ リミタータ | 改変された糖類、それらの結合体、およびそられの製造 |
JP2009242372A (ja) * | 2008-03-11 | 2009-10-22 | Yokohama City Univ | 均一な糖鎖構造を有するエリスロポエチン誘導体 |
JP2014043474A (ja) * | 2001-01-23 | 2014-03-13 | Sanofi Pasteur Inc | 多価髄膜炎菌多糖−タンパク質複合ワクチン |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040001842A1 (en) * | 1997-05-12 | 2004-01-01 | Dov Michaeli | Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors |
DE19821859A1 (de) * | 1998-05-15 | 1999-12-09 | M Alexander Schmidt | Darstellung immunogener (Kapsel-)Polysaccharid-Konjugate durch orientierte Kupplung synthetischer T-Zell-Epitope zur Erzeugung von Vakzinen gegen N.meningitidis |
US7223845B2 (en) | 1998-06-16 | 2007-05-29 | The Board Of Regents Of The University Of Oklahoma | Synthetic glycosulfopeptides and methods of synthesis thereof |
AU773542B2 (en) * | 1998-06-16 | 2004-05-27 | Board Of Regents Of The University Of Oklahoma, The | Glycosulfopeptides and methods of synthesis and use thereof |
US6858211B1 (en) * | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
US20030091574A1 (en) | 2001-03-23 | 2003-05-15 | Gevas Philip C. | Combination treatment of pancreatic cancer |
US20090191232A1 (en) | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
US20030035806A1 (en) * | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
US6695447B1 (en) | 2002-09-30 | 2004-02-24 | Eastman Kodak Company | Ink jet recording element |
US20050118199A1 (en) * | 2003-10-07 | 2005-06-02 | Esser Mark T. | Process for covalently conjugating polysaccharides to microspheres or biomolecules |
WO2006032980A1 (en) | 2004-09-22 | 2006-03-30 | Receptor Biologix, Inc. | Monoclonal antibolies to progastrin |
TWI264608B (en) * | 2005-04-08 | 2006-10-21 | Delta Electronics Inc | Light tunnel module |
ES2346693T3 (es) * | 2005-10-06 | 2010-10-19 | Nestec S.A. | Enterococos probioticos que permiten mejorar la unidad. |
TW200745163A (en) * | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
FR2899110A1 (fr) * | 2006-03-31 | 2007-10-05 | Sanofi Pasteur Sa | Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus |
LT2457920T (lt) | 2007-01-18 | 2018-02-12 | Genzyme Corporation | Oligosacharidai, apimantys aminooksigrupę, ir jų konjugatai |
EA201070231A1 (ru) * | 2007-08-09 | 2010-10-29 | Синтоникс Фармасьютикалз, Инк. | Иммуномодулирующие пептиды |
WO2010014909A1 (en) * | 2008-08-01 | 2010-02-04 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
JP5658167B2 (ja) | 2008-12-16 | 2015-01-21 | ジェンザイム・コーポレーション | オリゴ糖−タンパク複合体 |
NZ597007A (en) | 2009-05-14 | 2013-09-27 | Sanofi Pasteur | Meningococcus vaccine containing lipooligosaccharide (los) from modified strains of l6 immunotype neisseria meningitidis |
EP2429658B1 (fr) | 2009-05-14 | 2016-04-20 | Sanofi Pasteur | Procédé pour adjuver le lipopolysaccharide (LPS) des bactéries à gram-négatif |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
WO2013082149A1 (en) | 2011-11-28 | 2013-06-06 | Case Western Reserve University | Polysaccharide therapeutic conjugates |
WO2015184453A1 (en) | 2014-05-30 | 2015-12-03 | Case Western Reserve University | Retinylamine derivitives for treatment of ocular disorders |
US11129845B2 (en) | 2014-06-18 | 2021-09-28 | Case Western Reserve University | Compositions and methods for the delivery of nucleic acids |
US10925980B2 (en) | 2014-08-04 | 2021-02-23 | Case Western Reserve University | Molecular probes and methods of use |
US11407786B2 (en) | 2015-06-18 | 2022-08-09 | Case Western Reserve University | Compositions and methods for the delivery of nucleic acids |
WO2018232230A1 (en) | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695624A (en) * | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
NZ214503A (en) | 1984-12-20 | 1990-02-26 | Merck & Co Inc | Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates |
EP0326111A3 (en) | 1988-01-29 | 1989-12-27 | New York Blood Center, Inc. | Peptide derivatives rendered immunogenic when administered with alum as an adjuvant |
CA2047033A1 (en) | 1990-07-19 | 1992-01-20 | Elizabeth E. Sugg | Cyclic hiv principal neutralizing determinant peptides |
-
1998
- 1998-01-21 AT AT98906928T patent/ATE451124T1/de active
- 1998-01-21 NZ NZ331578A patent/NZ331578A/xx not_active IP Right Cessation
- 1998-01-21 US US09/155,077 patent/US6472506B1/en not_active Expired - Fee Related
- 1998-01-21 KR KR1019980707414A patent/KR100593466B1/ko not_active IP Right Cessation
- 1998-01-21 JP JP53376898A patent/JP4290766B2/ja not_active Expired - Fee Related
- 1998-01-21 AU AU62957/98A patent/AU722315B2/en not_active Ceased
- 1998-01-21 DE DE69841362T patent/DE69841362D1/de not_active Expired - Lifetime
- 1998-01-21 ES ES98906928T patent/ES2335557T3/es not_active Expired - Lifetime
- 1998-01-21 PT PT98906928T patent/PT959905E/pt unknown
- 1998-01-21 CA CA2246760A patent/CA2246760C/en not_active Expired - Fee Related
- 1998-01-21 WO PCT/EP1998/000654 patent/WO1998031393A2/en active IP Right Grant
- 1998-01-21 DK DK98906928.1T patent/DK0959905T3/da active
- 1998-01-21 EP EP98906928A patent/EP0959905B1/en not_active Expired - Lifetime
- 1998-09-18 NO NO19984341A patent/NO323870B1/no not_active IP Right Cessation
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014043474A (ja) * | 2001-01-23 | 2014-03-13 | Sanofi Pasteur Inc | 多価髄膜炎菌多糖−タンパク質複合ワクチン |
JP2014043475A (ja) * | 2001-01-23 | 2014-03-13 | Sanofi Pasteur Inc | 多価髄膜炎菌多糖−タンパク質複合ワクチン |
JP2014065745A (ja) * | 2001-01-23 | 2014-04-17 | Sanofi Pasteur Inc | 多価髄膜炎菌多糖−タンパク質複合ワクチン |
JP2016128526A (ja) * | 2001-01-23 | 2016-07-14 | サノフィ パストゥール インコーポレイテッド | 多価髄膜炎菌多糖−タンパク質複合ワクチン |
US9844601B2 (en) | 2001-01-23 | 2017-12-19 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
US10143757B2 (en) | 2001-01-23 | 2018-12-04 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
US10617766B2 (en) | 2001-01-23 | 2020-04-14 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
JP2006511465A (ja) * | 2002-08-30 | 2006-04-06 | カイロン ソチエタ ア レスポンサビリタ リミタータ | 改変された糖類、それらの結合体、およびそられの製造 |
JP2012017342A (ja) * | 2002-08-30 | 2012-01-26 | Novartis Vaccines & Diagnostics Srl | 改変された糖類、それらの結合体、およびそられの製造 |
JP2009242372A (ja) * | 2008-03-11 | 2009-10-22 | Yokohama City Univ | 均一な糖鎖構造を有するエリスロポエチン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
ES2335557T3 (es) | 2010-03-29 |
DE69841362D1 (de) | 2010-01-21 |
WO1998031393A2 (en) | 1998-07-23 |
PT959905E (pt) | 2010-02-05 |
JP4290766B2 (ja) | 2009-07-08 |
US6472506B1 (en) | 2002-10-29 |
CA2246760A1 (en) | 1998-07-23 |
NO984341L (no) | 1998-11-11 |
EP0959905B1 (en) | 2009-12-09 |
AU722315B2 (en) | 2000-07-27 |
AU6295798A (en) | 1998-08-07 |
CA2246760C (en) | 2012-01-10 |
NO984341D0 (no) | 1998-09-18 |
KR20000064696A (ko) | 2000-11-06 |
EP0959905A2 (en) | 1999-12-01 |
ATE451124T1 (de) | 2009-12-15 |
NO323870B1 (no) | 2007-07-16 |
WO1998031393A3 (en) | 1998-09-11 |
DK0959905T3 (da) | 2010-04-06 |
NZ331578A (en) | 2000-05-26 |
KR100593466B1 (ko) | 2007-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4290766B2 (ja) | 多糖―ペプチド複合体 | |
JP4097691B2 (ja) | C群髄膜炎菌に対するワクチン | |
CA1340956C (en) | Synthetic peptides representing a t-cell epitope as a carrier molecule for conjugate vaccines | |
US5425946A (en) | Vaccines against group C Neisseria meningitidis | |
JP2637845B2 (ja) | 修飾メニンゴコツクス多糖複合ワクチン | |
JP4001625B2 (ja) | 2,5−アンヒドロ−d−マンノース末端構造を持つ、抗原性グループb連鎖球菌2型および3型多糖断片とその複合ワクチン | |
JP2004505885A (ja) | N−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体 | |
HUT64237A (en) | Improved vaccina preparatives | |
JPH11506491A (ja) | 修飾したメニンゴコッカスのポリサッカライドを結合したワクチン | |
KR101044437B1 (ko) | 5 혈청형 폐렴연쇄구균 피막 폴리사카라이드의 환원적아민화에 의해 수득된 접합체 | |
US5952454A (en) | Linking compounds useful for coupling carbohydrates to amine-containing carriers | |
Kihlberg et al. | Use of carbohydrates and peptides in studies of adhesion of pathogenic bacteria and in efforts to generate carbohydrate-specific T cells | |
JP2000507274A (ja) | キャリヤーペプチドとしてのiga1プロテアーゼフラグメント | |
MXPA98007617A (es) | Conjugados de polisacaridos peptidos | |
MXPA98007634A (en) | Iga1 protease fragment as carrier peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041118 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20060131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080415 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090303 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090402 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120410 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130410 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |